Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807629 | 1.00 | PTGS1 (0.45) | PTGS1GSTK1GRIK1GRIK2GRM1 | |
| SCHEMBL359953 | 0.84 | SLC1A1 (0.45) | PTGS1GRIK1GRIK2GRM1GRM2 | |
| Leucine SCHEMBL20899395 | 0.84 | SLC7A5 (0.60) | PTGS1GSTK1GRIK1GRIK2SLC1A1 | |
| SCHEMBL12156958 | 0.80 | RECQL (0.50) | GRIK1GRIK2GRM1GRM2SLC1A1 | |
| SCHEMBL2459448 | 0.79 | PTGS1 (0.62) | PTGS1GSTK1GRIK1GRIK2GRM1 | |
| SCHEMBL1769059 | 0.79 | PTGS1 (0.62) | PTGS1GSTK1GRIK1GRIK2GRM1 | |
| SCHEMBL1769055 | 0.79 | PTGS1 (0.62) | PTGS1GSTK1GRIK1GRIK2GRM1 | |
| SCHEMBL9081685 | 0.78 | ALDH1A1 (0.47) | — | |
| SCHEMBL11218033 | 0.78 | GRIK1 (0.48) | PTGS1GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL1512966 | 0.78 | GRIK1 (0.47) | GRIK1GRIK2GRM1GRM2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143197-A | Peptides for targeted expression of Nectin-4 cells for treating cancers and application thereof | 主流源生物科技(上海)有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| EP-2207525-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'Oréal (FR) | 2010-07-21 | — | — | EP | claimed |
| EP-2205201-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'Oreal (FR) | 2010-07-14 | — | — | EP | claimed |
| WO-2009053594-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053587-A2 | COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053584-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | disclosed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117143197-A | Peptides for targeted expression of Nectin-4 cells for treating cancers and application thereof | 主流源生物科技(上海)有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-1440165-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | MILLENNIUM PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050009053-A1 | Fragmentation-based methods and systems for de novo sequencing | SEQUENOM, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004097369-A2 | FRAGMENTATION-BASED METHODS AND SYSTEMS FOR DE NOVO SEQUENCING | SEQUENOM, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1440165-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | Millennium Pharmaceuticals, Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030124593-A1 | Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 | MILLENNIUM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003038113-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELLULAR PROLIFERATION DISORDERS USING 25943 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | PTGS1 1219/4885GSTK1 3253/4885GRIK1 1372/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | PTGS1 2251/4885GSTK1 2512/4885GRIK1 2925/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | PTGS1 717/4885GSTK1 3914/4885GRIK1 670/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | PTGS1 1928/4885GSTK1 1238/4885GRIK1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.